Study of Nemtabrutinib vs ibrutinib or acalabrutinib for untreated CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL or SLL and need to start treatment now.
- You are able to swallow and keep down pills.
- You have not had any prior treatment for CLL/SLL (like chemotherapy or targeted drugs).
- You do not have active hepatitis B or C, or other serious infections.
- You do not have serious heart, bleeding, or stomach problems.
- You are not taking certain other medications that could interfere with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (nemtabrutinib and venetoclax) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have never received cancer treatment before. The goal is to see if this combination can shrink the cancer and help patients live longer.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This trial tests a combination of three drugs (nemtabrutinib, venetoclax, and obinutuzumab) for people with CLL or SLL who need treatment but haven't taken similar targeted therapies before. It aims to see if this new cocktail works better together.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.